{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:58Z","timestamp":1792194958697,"version":"4.4.0"},"reference-count":336,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010618","name":"Guangzhou University of Chinese Medicine","doi-asserted-by":"publisher","award":["GZY2025ZJ30"],"award-info":[{"award-number":["GZY2025ZJ30"]}],"id":[{"id":"10.13039\/501100010618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010618","name":"Guangzhou University of Chinese Medicine","doi-asserted-by":"publisher","award":["09005647001"],"award-info":[{"award-number":["09005647001"]}],"id":[{"id":"10.13039\/501100010618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.drup.2026.101447","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:39:59Z","timestamp":1783957199000},"page":"101447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunotherapy in cancer: Mechanisms and strategies to overcome resistance"],"prefix":"10.1016","volume":"89","author":[{"given":"Haigan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-8931","authenticated-orcid":false,"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Xun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles R.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101447_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/14712598.2012.693473","article-title":"Antibody\u2013drug conjugates\u2013a perfect synergy","volume":"12","author":"Adair","year":"2012","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2026.101447_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2026.101447_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101447_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-4939-9929-3_4","article-title":"Site-specific conjugation to Cys-engineered THIOMAB\u2122 antibodies","author":"Adhikari","year":"2020","journal-title":"Antib. -Drug. Conjug. Methods Protoc."},{"key":"10.1016\/j.drup.2026.101447_bib6","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer","author":"Ahn","year":"2024","journal-title":"Random Open. -Label. phase III TROPION-Lung01 Study J. Clin. Oncol. JCO-24-01544."},{"key":"10.1016\/j.drup.2026.101447_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091164","article-title":"Strategic and Chemical Advances in Antibody-Drug Conjugates","volume":"17","author":"Alradwan","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drup.2026.101447_bib8","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-4553","article-title":"The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control","author":"Amann","year":"2020","journal-title":"Cancer Res. 80 2. <Go ISI>\/\/WOS"},{"key":"10.1016\/j.drup.2026.101447_bib9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell. Metab."},{"key":"10.1016\/j.drup.2026.101447_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101447_bib11","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00259-021-05653-0","article-title":"Translational imaging of the fibroblast activation protein (FAP) using the new ligand [(68)Ga]Ga-OncoFAP-DOTAGA","volume":"49","author":"Backhaus","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.drup.2026.101447_bib12","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/bc500148x","article-title":"Bridging disulfides for stable and defined antibody drug conjugates","volume":"25","author":"Badescu","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.drup.2026.101447_bib13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/bc500148x","article-title":"Bridging disulfides for stable and defined antibody drug conjugates","volume":"25","author":"Badescu","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.drup.2026.101447_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","article-title":"Trastuzumab emtansine: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101447_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101447_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","article-title":"Endocytosis in cancer and cancer therapy","volume":"23","author":"Banushi","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","article-title":"Endocytosis in cancer and cancer therapy","volume":"23","author":"Banushi","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor\u2013Positive Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2013and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol. JCO"},{"key":"10.1016\/j.drup.2026.101447_bib21","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib22","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.drup.2026.101447_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101447_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101447_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib27","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-2288","article-title":"Investigational CD25 x CTLA-4 bispecific DART\u00ae molecule for depletion of tumor infiltrating Tregs via an enhanced Fc-dependent effector mechanism","author":"Berezhnoy","year":"2020","journal-title":"Cancer Res. 80 2. <Go ISI>\/\/WOS"},{"key":"10.1016\/j.drup.2026.101447_bib28","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3324\/haematol.2009.008862","article-title":"Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma\u2013analyses of cases from two prospective randomized clinical trials","volume":"94","author":"Bernd","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101447_bib29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101447_bib30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.drup.2026.101447_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell. Metab."},{"key":"10.1016\/j.drup.2026.101447_bib32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","volume":"355","author":"Breedveld","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101447_bib33","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/eji.200838289","article-title":"Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells","volume":"38","author":"Cham","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib34","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.4049\/jimmunol.174.8.4670","article-title":"Glucose availability regulates IFN-\u03b3 production and p70S6 kinase activation in CD8+ effector T cells","volume":"174","author":"Cham","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1042\/BST20231332","article-title":"Targeting endocytosis to sensitize cancer cells to programmed cell death","volume":"52","author":"Chan","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.drup.2026.101447_bib36","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1042\/BST20231332","article-title":"Targeting endocytosis to sensitize cancer cells to programmed cell death","volume":"52","author":"Chan","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.drup.2026.101447_bib37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101447_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.drup.2026.101447_bib39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.drup.2026.101447_bib40","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101447_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41423-022-00926-6","article-title":"Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1","volume":"19","author":"Chen","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.drup.2026.101447_bib46","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2026.101447_bib47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2008.303","article-title":"Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases","volume":"23","author":"Chevallier","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101447_bib48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2020.02.019","article-title":"Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies","volume":"180","author":"Chew","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101447_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic\u2014a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib50","first-page":"355","article-title":"Evolving standards of care and new challenges in the management of HER2-positive breast cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101447_bib51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib52","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101447_bib53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib55","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2020.1796","article-title":"Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial","volume":"6","author":"Cort\u00e9s","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib56","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101447_bib57","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101447_bib59","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","article-title":"Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?","volume":"68","author":"De Charette","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib62","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-L\u00f3pez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib63","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101447_bib64","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101447_bib65","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/bc400574z","article-title":"Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody\u2013drug conjugates","volume":"25","author":"Dennler","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.drup.2026.101447_bib66","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101447_bib67","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1001\/jama.1982.03330230065038","article-title":"Monoclonal antibodies","volume":"248","author":"Diamond","year":"1982","journal-title":"Jama"},{"key":"10.1016\/j.drup.2026.101447_bib68","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-023-01411-x","article-title":"Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting","volume":"16","author":"DiNardo","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib70","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ni.2714","article-title":"Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen","volume":"14","author":"Doedens","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib71","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101447_bib72","first-page":"2721","article-title":"Therapeutic potential of an anti-CD79b antibody\u2013drug conjugate, anti\u2013CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101447_bib73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102672","article-title":"Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)","volume":"123","author":"Dri","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101447_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41420-024-01845-3","article-title":"Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase","volume":"10","author":"El Alaoui","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.drup.2026.101447_bib76","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.molpharmaceut.2c00392","article-title":"Design and characterization of immune-stimulating imidazo [4, 5-c] quinoline antibody-drug conjugates","volume":"19","author":"Fang","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2026.101447_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.drup.2026.101447_bib78","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jacsau.2c00448","article-title":"40 years of duocarmycins: a graphical structure\/function review of their chemical evolution, from SAR to prodrugs and ADCs","volume":"2","author":"Felber","year":"2022","journal-title":"JACS Au"},{"key":"10.1016\/j.drup.2026.101447_bib79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J. Immunother."},{"key":"10.1016\/j.drup.2026.101447_bib80","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101447_bib81","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101447_bib82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101447_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the Immune-Stimulating Antibody Conjugates (ISACs) be transferred from bench to bedside?","author":"Fu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drup.2026.101447_bib84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101447_bib85","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib87","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib88","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101447_bib89","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody\u2013drug conjugates","volume":"78","author":"Garcia-Alonso","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101447_bib91","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101447_bib92","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41571-025-01008-y","article-title":"Emerging importance of HER3 in tumorigenesis and cancer therapy","volume":"22","author":"Garrett","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib93","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101447_bib94","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.adh7954","article-title":"Vitamin D regulates microbiome-dependent cancer immunity","volume":"384","author":"Giampazolias","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101447_bib95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib96","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101447_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","author":"Graus-Porta","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.drup.2026.101447_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aao6869","article-title":"A recycling program that keeps PD-L1 out of the cancer cell's junkyard","volume":"2","author":"Griffin","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib99","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib100","article-title":"Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Advanced science (Weinheim Baden-Wurttemberg Germany)"},{"key":"10.1016\/j.drup.2026.101447_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002202","article-title":"Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions","volume":"13","author":"Haas","year":"2015","journal-title":"PLoS. Biol."},{"key":"10.1016\/j.drup.2026.101447_bib102","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.semcancer.2022.02.019","article-title":"Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions","volume":"86","author":"Haddad","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2026.101447_bib103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.drup.2026.101447_bib104","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.drup.2026.101447_bib105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)\u2014a necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drup.2026.101447_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081707","article-title":"The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates","volume":"14","author":"Han","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drup.2026.101447_bib107","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101447_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.671","article-title":"Antibody\u2013drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.drup.2026.101447_bib109","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100849","article-title":"New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug. Resist. Updates"},{"key":"10.1016\/j.drup.2026.101447_bib111","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.3390\/molecules24183287","article-title":"Site selective antibody-oligonucleotide conjugation via microbial transglutaminase","volume":"24","author":"Huggins","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2026.101447_bib112","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma","author":"Hungria","year":"2024","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib113","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib114","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/ph14040343","article-title":"Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches","volume":"14","author":"Hussain","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drup.2026.101447_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells?","volume":"38","author":"Icard","year":"2018","journal-title":"Drug. Resist. Updates"},{"key":"10.1016\/j.drup.2026.101447_bib116","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201780R","article-title":"A universal method to analyze cellular internalization mechanisms via endocytosis without non-specific cross-effects","volume":"37","author":"Itagaki","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.drup.2026.101447_bib117","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.24987","article-title":"Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2026.101447_bib118","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement","author":"Jiang","year":"2024","journal-title":"Drug. Resist. Updates"},{"key":"10.1016\/j.drup.2026.101447_bib120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.bbrc.2023.10.037","article-title":"Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma","volume":"682","author":"Jiao","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101447_bib121","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101447_bib122","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2026.101447_bib123","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/316820a0","article-title":"Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies","volume":"316","author":"Kartner","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib124","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab Deruxtecan: First Approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101447_bib125","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib126","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib127","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/biomedicines12081801","article-title":"Overcoming cancer resistance: Strategies and modalities for effective treatment","volume":"12","author":"Koirala","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2026.101447_bib128","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol. & Med."},{"key":"10.1016\/j.drup.2026.101447_bib129","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An Attractive Target for Antibody-based Immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.drup.2026.101447_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug. Resist. Updates"},{"key":"10.1016\/j.drup.2026.101447_bib131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101447_bib132","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101447_bib133","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib134","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib135","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101447_bib136","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101447_bib137","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13058-016-0691-7","article-title":"Phase 1b\/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer","volume":"18","author":"Krop","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib138","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","article-title":"Exploiting bacteria for cancer immunotherapy","volume":"21","author":"Kwon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib139","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib140","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib141","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: First Approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101447_bib142","doi-asserted-by":"crossref","first-page":"a020768","DOI":"10.1101\/cshperspect.a020768","article-title":"The EGFR family: not so prototypical receptor tyrosine kinases","volume":"6","author":"Lemmon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.drup.2026.101447_bib143","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2026.101447_bib144","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib145","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7150\/ijbs.39769","article-title":"Comprehensive understanding of B7 family in gastric cancer: expression profile, association with clinicopathological parameters and downstream targets","volume":"16","author":"Li","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib146","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7150\/ijbs.39769","article-title":"Comprehensive understanding of B7 family in gastric cancer: expression profile, association with clinicopathological parameters and downstream targets","volume":"16","author":"Li","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib147","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101447_bib148","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-\u03b2 regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib149","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.drup.2026.101447_bib150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib151","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cells11091583","article-title":"An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101447_bib152","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41467-024-45340-w","article-title":"UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101447_bib153","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41467-024-45340-w","article-title":"UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101447_bib154","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib155","series-title":"Cellular Metabolic Dynamics","first-page":"35","article-title":"The Internalization and Intracellular Trafficking of ADCs, in: Antibody-Drug Conjugates and","author":"Liang","year":"2023"},{"key":"10.1016\/j.drup.2026.101447_bib156","article-title":"Metabolic Reprogramming of Glycolysis, Lipids, and Amino Acids in Tumors: Impact on CD8+ T Cell Function and Targeted Therapeutic Strategies. Faseb j","volume":"39","author":"Liang","year":"2025"},{"key":"10.1016\/j.drup.2026.101447_bib157","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semcancer.2022.12.011","article-title":"Tumor hypoxia: From basic knowledge to therapeutic implications","volume":"88","author":"Liao","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2026.101447_bib158","article-title":"Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed. & Pharmacother. = Biomedecine & Pharmacother."},{"key":"10.1016\/j.drup.2026.101447_bib159","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib160","first-page":"988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101447_bib161","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101447_bib162","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101447_bib163","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-017-0541-9","article-title":"Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib164","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101447_bib165","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.drup.2026.101447_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115984","article-title":"The emerging roles of PD-L1 subcellular localization in tumor immune evasion","volume":"220","author":"Liu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2026.101447_bib167","article-title":"Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib168","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib170","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101447_bib171","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21342","article-title":"Perspectives on biologically active camptothecin derivatives","volume":"35","author":"Liu","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drup.2026.101447_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100886","article-title":"N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells","volume":"65","author":"Liu","year":"2022","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101447_bib173","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2026.101447_bib174","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101447_bib175","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab\u2013maytansinoid antibody\u2013drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101447_bib176","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101447_bib177","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib178","first-page":"6050","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101447_bib179","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1021\/ja4059525","article-title":"Site-specific antibody\u2013polymer conjugates for siRNA delivery","volume":"135","author":"Lu","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drup.2026.101447_bib180","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody\u2013drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib181","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib182","article-title":"Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt\/\u03b2-Catenin Pathway in Human Non-Small Cell Lung Cancer","volume":"23","author":"Ma","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib183","first-page":"1","article-title":"An overview of receptor endocytosis and signaling","volume":"194","author":"Mani","year":"2023","journal-title":"Progress. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib184","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.drup.2026.101447_bib185","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdw157","article-title":"Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib\/IIa study","volume":"27","author":"Martin","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib186","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.abg5784","article-title":"The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation","volume":"373","author":"Martin","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101447_bib187","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1021\/jacs.7b12698","article-title":"Synthesis of the Death-Cap Mushroom Toxin \u03b1-Amanitin","volume":"140","author":"Matinkhoo","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drup.2026.101447_bib188","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3109\/10428194.2012.656102","article-title":"Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin","volume":"53","author":"Matsumoto","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.drup.2026.101447_bib189","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fcell.2016.00027","article-title":"Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction","volume":"4","author":"McDonald","year":"2016","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.drup.2026.101447_bib191","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101447_bib192","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib193","doi-asserted-by":"crossref","first-page":"a016949","DOI":"10.1101\/cshperspect.a016949","article-title":"Endocytosis and cancer","volume":"5","author":"Mellman","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.drup.2026.101447_bib194","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib195","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101852118","article-title":"An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications","volume":"118","author":"Millul","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101447_bib196","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101447_bib197","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes","volume":"15","author":"Mittendorf","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib198","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes","volume":"15","author":"Mittendorf","year":"2009","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.drup.2026.101447_bib199","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.3390\/cancers15215117","article-title":"Review of RM-1929 near-infrared photoimmunotherapy clinical efficacy for unresectable and\/or recurrent head and neck squamous cell carcinoma","volume":"15","author":"Miyazaki","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101447_bib200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib201","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1093\/annonc\/mds200","article-title":"Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer","volume":"23","author":"Mohd Sharial","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib202","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of (68)Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study","volume":"63","author":"Mona","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.drup.2026.101447_bib203","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.3390\/cancers15153801","article-title":"Systemic therapy for metastatic triple negative breast cancer: Current treatments and future directions","volume":"15","author":"Morrison","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101447_bib204","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/biomimetics3030019","article-title":"Alterations in cellular processes involving vesicular trafficking and implications in drug delivery","volume":"3","author":"Muro","year":"2018","journal-title":"Biomimetics"},{"key":"10.1016\/j.drup.2026.101447_bib206","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1111\/cas.13827","article-title":"Reinforce the antitumor activity of CD 8+ T cells via glutamine restriction","volume":"109","author":"Nabe","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101447_bib207","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101447_bib208","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(23)00479-X","article-title":"Targeting the EGFR signalling pathway in metastatic colorectal cancer","author":"Napolitano","year":"2024","journal-title":"Lancet Gastroenterol. & Hepatol."},{"key":"10.1016\/j.drup.2026.101447_bib210","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-025-03697-y","article-title":"Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies","volume":"25","author":"Nasiri","year":"2025","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.drup.2026.101447_bib211","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability\u2014an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.drup.2026.101447_bib212","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101447_bib213","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004605","article-title":"Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells","volume":"10","author":"Noyes","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib214","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ijc.32193","article-title":"search of definitions: Cancer-associated fibroblasts and their markers","volume":"146","author":"Nurmik","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib215","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2024.1428713","article-title":"Safety and efficacy of toll-like receptor agonists as therapeutic agents and vaccine adjuvants for infectious diseases in animals: a systematic review","volume":"11","author":"Oboge","year":"2024","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib216","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib217","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody\u2013drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101447_bib218","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1073\/pnas.1820388116","article-title":"Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity","volume":"116","author":"Onda","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib219","doi-asserted-by":"crossref","first-page":"10113","DOI":"10.1073\/pnas.0711106105","article-title":"Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation","volume":"105","author":"Onishi","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib220","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug. Resist. Update. Rev. Comment. Antimicrob. Anticancer. Chemother."},{"issue":"14","key":"10.1016\/j.drup.2026.101447_bib221","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","article-title":"Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts","volume":"14","author":"Ostermann","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.drup.2026.101447_bib222","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101447_bib223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0840-y","article-title":"Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy","volume":"17","author":"Pang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib224","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3390\/ijms24032971","article-title":"Insights of endocytosis signaling in health and disease","volume":"24","author":"Pathak","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib225","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","article-title":"Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models","volume":"18","author":"Ponte","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.drup.2026.101447_bib226","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib227","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1039\/D2NR05421C","article-title":"Endocytosis-mediated redistribution of antibiotics targets intracellular bacteria","volume":"15","author":"Qu","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.drup.2026.101447_bib228","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib229","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07961","article-title":"The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins","volume":"458","author":"Raiborg","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib230","first-page":"109","article-title":"Mechanisms of resistance to immune checkpoint antibodies","author":"Ramos","year":"2018","journal-title":"Mech. Drug. Resist. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101447_bib231","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib232","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib233","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.drup.2026.101447_bib234","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","article-title":"Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival","volume":"108","author":"Roberts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101447_bib236","first-page":"255","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"Journal experimental & clinical cancer research CR"},{"key":"10.1016\/j.drup.2026.101447_bib237","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib238","first-page":"58","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101447_bib239","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101447_bib240","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101447_bib241","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13036-023-00345-9","article-title":"Rapid, simple, and effective strategy to produce monoclonal antibodies targeting protein structures using hybridoma technology","volume":"17","author":"Sakaguchi","year":"2023","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.drup.2026.101447_bib242","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib243","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101447_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109805","article-title":"Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis","author":"Salvestrini","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib245","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2308097","article-title":"A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance","volume":"25","author":"Santiago-S\u00e1nchez","year":"2024","journal-title":"Cancer Biol. & Ther."},{"key":"10.1016\/j.drup.2026.101447_bib246","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.drup.2026.101447_bib247","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol. 20 531-544. <Go ISI>\/\/WOS"},{"key":"10.1016\/j.drup.2026.101447_bib248","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.drup.2026.101447_bib249","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.556","article-title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Updated results from BEGONIA, a phase Ib\/II study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrc3366","article-title":"Controlling escape from angiogenesis inhibitors","volume":"12","author":"Sennino","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib251","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib252","first-page":"553","article-title":"Molecular physiology of receptor mediated endocytosis and its role in overcoming multidrug resistance","volume":"97","author":"Severin","year":"2011","journal-title":"Ross. Fiziol. Zh IM. IM Sechenova"},{"key":"10.1016\/j.drup.2026.101447_bib253","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.drup.2026.101447_bib254","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance\u2014challenges and solutions","volume":"18","author":"Shefet-Carasso","year":"2015","journal-title":"Drug. Resist. Updates"},{"key":"10.1016\/j.drup.2026.101447_bib255","doi-asserted-by":"crossref","first-page":"9394","DOI":"10.1038\/s41467-024-53593-8","article-title":"HIF1\u03b1-regulated glycolysis promotes activation-induced cell death and IFN-\u03b3 induction in hypoxic T cells","volume":"15","author":"Shen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101447_bib256","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib257","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101447_bib258","first-page":"1","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101447_bib259","series-title":"in: Semin Cancer Biol","first-page":"3","article-title":"Monoclonal antibodies for the treatment of cancer","author":"Shuptrine","year":"2012"},{"key":"10.1016\/j.drup.2026.101447_bib260","first-page":"426","article-title":"T-DXd is effective after T-DM1","volume":"20","author":"Sidaway","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib261","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib262","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib263","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1526250","article-title":"Trial Watch: Toll-like receptor agonists in cancer immunotherapy","volume":"7","author":"Smith","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drup.2026.101447_bib264","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101447_bib265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib266","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib267","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib268","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.drup.2026.101447_bib269","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101447_bib270","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101447_bib271","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101447_bib272","first-page":"3128","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101447_bib273","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114304","article-title":"Topoisomerase I inhibitors: Challenges, progress and the road ahead","volume":"236","author":"Talukdar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101447_bib274","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2131084","article-title":"Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers","volume":"11","author":"Tang","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.drup.2026.101447_bib275","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41581-022-00587-8","article-title":"The effect of HIF on metabolism and immunity","volume":"18","author":"Taylor","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.drup.2026.101447_bib276","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101447_bib277","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.3390\/cancers15225384","article-title":"Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches","volume":"15","author":"Tojjari","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101447_bib278","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib279","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101447_bib280","series-title":"in: Semin Cancer Biol","first-page":"151","article-title":"How does P-glycoprotein recognize its substrates?","author":"Ueda","year":"1997"},{"key":"10.1016\/j.drup.2026.101447_bib281","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-19-1985","article-title":"Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: biomarker post hoc analysis of the VELOUR trial","volume":"26","author":"Van Cutsem","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib282","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg\u00ae) treatment in acute myeloid leukemia patients","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101447_bib283","first-page":"3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"van der Velden","year":"2001","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101447_bib284","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes","author":"Venkatesan","year":"2024","journal-title":"Pharmacol. & Ther."},{"key":"10.1016\/j.drup.2026.101447_bib285","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib286","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121647","article-title":"Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer","volume":"8","author":"Vetsika","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101447_bib287","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101447_bib288","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1039\/C8SC04645J","article-title":"A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody\u2013drug conjugates","volume":"10","author":"Walsh","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib289","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood-2003-11-3825","article-title":"The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin","volume":"103","author":"Walter","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101447_bib290","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.drup.2026.101447_bib291","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111989","article-title":"Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies","volume":"132","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drup.2026.101447_bib292","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib293","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drup.2026.101447_bib294","article-title":"Antibody\u2013drug conjugates: Recent advances in payloads","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2026.101447_bib295","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-022-02327-y","article-title":"Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR\/MSI-H gastric adenocarcinoma","volume":"20","author":"Wang","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.drup.2026.101447_bib296","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-022-02327-y","article-title":"Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR\/MSI-H gastric adenocarcinoma","volume":"20","author":"Wang","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.drup.2026.101447_bib297","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101447_bib298","series-title":"in: Semin Cancer Biol","first-page":"38","article-title":"Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle","author":"Wattenberg","year":"2020"},{"key":"10.1016\/j.drup.2026.101447_bib299","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101447_bib300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.02.022","article-title":"PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways","volume":"450","author":"Wei","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101447_bib301","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.02.022","article-title":"PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways","volume":"450","author":"Wei","year":"2019","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.drup.2026.101447_bib302","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib303","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","article-title":"Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.drup.2026.101447_bib304","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101447_bib305","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.drup.2026.101447_bib306","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1182\/blood-2022-162406","volume":"140","author":"Westervelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101447_bib307","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib308","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib309","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib310","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1038\/s41467-020-17756-7","article-title":"T-cells produce acidic niches in lymph nodes to suppress their own effector functions","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101447_bib311","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1021\/acs.bioconjchem.1c00342","article-title":"Precision modification of native antibodies","volume":"32","author":"Wu","year":"2021","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.drup.2026.101447_bib312","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1","volume":"35","author":"Wu","year":"2023","journal-title":"Cell. Metab."},{"key":"10.1016\/j.drup.2026.101447_bib313","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib314","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41419-018-1291-5","article-title":"Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization","volume":"10","author":"Xiang","year":"2019","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.drup.2026.101447_bib315","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101447_bib316","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103012","article-title":"Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy","volume":"140","author":"Xu","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101447_bib317","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-023-01453-1","article-title":"Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy","volume":"16","author":"Yang","year":"2023","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib318","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","article-title":"TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti\u2013PD-1 response in follicular lymphoma","volume":"26","author":"Yang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib319","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1158\/1078-0432.CCR-08-2814","article-title":"Suppression of HER2\/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab","volume":"15","author":"Yao","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib320","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202206411","article-title":"Manipulation of PD-L1 Endosomal Trafficking Promotes Anticancer Immunity","volume":"10","author":"Ye","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2026.101447_bib321","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101447_bib322","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.847835","article-title":"Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers","volume":"9","author":"Yu","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.drup.2026.101447_bib323","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101447_bib324","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1158\/1078-0432.CCR-22-1788","article-title":"Fibroblast Activation Protein Triggers Release of Drug Payload from Non-internalizing Small Molecule Drug Conjugates in Solid Tumors","volume":"28","author":"Zana","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101447_bib325","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101447_bib326","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217112","article-title":"PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer","volume":"598","author":"Zhang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101447_bib327","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1111\/febs.15028","article-title":"The influence of microenvironment on tumor immunotherapy","volume":"286","author":"Zhang","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.drup.2026.101447_bib328","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib329","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ni.3313","article-title":"Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction","volume":"17","author":"Zhao","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib330","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3892\/ol.2020.11647","article-title":"PD\u2011L1 expression increased by IFN\u2011\u03b3 via JAK2\u2011STAT1 signaling and predicts a poor survival in colorectal cancer","volume":"20","author":"Zhao","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101447_bib331","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.smim.2017.12.004","article-title":"Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells","volume":"35","author":"Zhou","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.drup.2026.101447_bib332","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101447_bib333","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/molecules28030917","article-title":"Site-specific antibody conjugation with payloads beyond cytotoxins","volume":"28","author":"Zhou","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2026.101447_bib334","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215598","article-title":"PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer","volume":"532","author":"Zhou","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101447_bib335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2026.101447_bib336","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202201887","article-title":"Thioester-Assisted Sortase-A-Mediated Ligation","volume":"134","author":"Zuo","year":"2022","journal-title":"Angew. Chem."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:10:07Z","timestamp":1789787407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":336,"alternative-id":["S1368764626000981"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101447","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in cancer: Mechanisms and strategies to overcome resistance","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101447"}}